Therefore, we sought to determine how truncated variants shape AR chromatin occupancy and responses to treatments in both the presence and absence of full-length AR.<h4>Methods</h4>We used a cohort of patient-derived xenografts of metastatic prostate cancer with diverse AR alterations. This evidence concerns the gene AR and metastatic prostate carcinoma.